Related Experiment Video

Updated: Sep 10, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.4K

Classic Hairy Cell Leukemia With MAP2K1 Mutation: Diagnosis and Targeted Therapy

Andrea Duminuco1, Alessandra Venanzi2, Alessia Santi2

  • 1Institute of Hematology, University and Hospital of Catania, Catania, Italy.

American Journal of Hematology
|August 23, 2025
PubMed
Abstract

No abstract available in PubMed .

Keywords:
MAP2K1 mutationhairy cell leukemianeoplasia‐lymphoid leukemiasneoplasia‐pharmacotherapeuticstargeted therapy

More Related Videos

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.3K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K

Related Experiment Videos

Last Updated: Sep 10, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.4K
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.3K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K

Articles linked to this work by shared authors, journal, and citation graph.

Janus kinase inhibitors after ruxolitinib failure in myelofibrosis: A systematic review and pooled analysis of phase 3 efficacy and integrated safety across clinical trials and real-world evidence.

British journal of haematology·2026

Hepcidin as a Molecular Hub of Iron Homeostasis: From BMP-SMAD Signaling to Therapeutic Modulation.

Biomolecules·2026

Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience.

British journal of haematology·2026

A systematic review of 47 published cases of extramedullary hematopoiesis in myelofibrosis: clinical patterns, treatment responses, and prognostic implications.

Annals of hematology·2026

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study.

Cancer·2026

Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes.

Leukemia·2026

Myeloma Elderly Prognostic Score (MEPS): A Proposed Prognostic Score Integrating Age, Renal Function, Performance Status, and Ultra-High-Risk Cytogenetics.

American journal of hematology·2026

Older Age, STAG2, and DNMT3A Mutations Predict Superior Posttransplant Survival in Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents.

American journal of hematology·2026

Mitigating HLA Disparity in AML Transplantation: Comparable Outcomes After Haploidentical and 9/10 Mismatched Unrelated Donor Transplantation With Treosulfan and PTCy.

American journal of hematology·2026

Clinically Relevant Outcomes With Romiplostim in Patients With Solid Tumors and Persistent Chemotherapy Induced Thrombocytopenia.

American journal of hematology·2026

Multiple Myeloma: 2026 Update on Diagnosis, Risk-Stratification and Management.

American journal of hematology·2026

Navigating Asparaginase Treatment for Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations on the Role of Multidisciplinary Care.

American journal of hematology·2026

Polycation chain length determines the in vivo mRNA delivery efficiency of block copolymer micelles.

Biomaterials science·2026

Driving Drugs Deeper: Force-Driven Microneedle Systems for Active Therapy and Their Road Towards Clinical Implementation.

Small (Weinheim an der Bergstrasse, Germany)·2026

Mumio Potentiates Temozolomide by Inducing Apoptosis and Ferroptosis in Glioblastoma Cells.

Current pharmaceutical design·2026

Current Targeted Nanoparticle Therapy for Alzheimer's Disease: Current Advances and Future Prospects.

Current neurovascular research·2026

Clinical Presentation, Diagnosis, Treatment, and Outcome of Heart Disease in Becker Muscular Dystrophy.

Anatolian journal of cardiology·2026

Clinical Pharmacology of Eplontersen, the First Approved GalNAc-Conjugated Antisense Oligonucleotide.

Journal of clinical pharmacology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us